Blood concentration monitoring during high-dose methotrexate treatment.
- Author:
Li JIAO
1
;
Dao-Bin ZHOU
;
Shu-Jie WANG
;
Wei ZHANG
;
Ming-Hui DUAN
;
Jian LI
;
Bing HAN
;
Ying XU
;
Yong-Qiang ZHAO
;
Ti SHEN
;
Qiang WANG
;
Min YE
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; administration & dosage; blood; therapeutic use; Drug Monitoring; Female; Humans; Lymphoma; drug therapy; Male; Methotrexate; administration & dosage; blood; therapeutic use; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; drug therapy; Young Adult
- From: Acta Academiae Medicinae Sinicae 2009;31(5):564-566
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the clinical value of blood concentration monitoring during high-dose methotrexate (MTX) treatment.
METHODSHigh-dose MTX (1.5-9.0 g) was infused to 105 patients with acute lymphoblastic leukemia or lymphoma, and then the blood MTX concentration was measured by fluorescence polarization immune assay (FPIA) 44 hours after the start of administration. The procedure was repeated every 6-12 hours until the concentration was less than 0.1 micromol/L.
RESULTSForty-four hours after the start of administration, the blood MTX concentration (C(MTX/44h)) was > or = 5 micromol/L in 6 patients (2.8%) and was between 1 and 5 micromol/L in 23 patients (10.6%). C(MTX/44h) > or = 1 micromol/L was more common in patients received 5.0 g MTX. No severe adverse event was observed in all patients.
CONCLUSIONSBlood MTX concentration is different after high-dose MTX treatment due to individual metabolic differences, and therefore it is clinically important to monitor blood concentration of MTX. Elimination delay is more common in patients receive 5.0 g MTX. Application of high-dose MTX therapy under the monitoring of blood MTX concentration is safe and feasible.
